

ABSTRACT

CRYSTALLINE COMPOUND OR BASIC SALT THEREOF, PREPARATION
METHOD THEREFOR, AND USE THEREOF

5

The present invention relates to a crystalline compound or a basic salt thereof, a preparation method therefor, and a use thereof. The compound is a PD-1/PD-L1 inhibitor having a compound structure as represented by the following formula (I). The crystalline compound has moderate hygroscopicity, improved solubility, good crystallinity, and stable physicochemical properties, and the basic salt of the crystalline compound has good crystallinity, good solubility, and stable physicochemical properties, meets industrial production requirements, and satisfies the need for the development of clinical pharmaceutical formulations. The crystalline compound or the basic salt thereof in the present invention can be widely applied to the preparation of drugs for treating PD-1/PD-L1 signaling pathway-mediated tumors, immune-related diseases and disorders, contagious diseases, infectious diseases, or metabolic diseases.

